Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20)
Language
- English (20) (remove)
Keywords
- HIV (4)
- antiretroviral therapy (3)
- German Hepatitis C-Registry (2)
- chronic hepatitis C (2)
- graft versus host disease (2)
- hepatitis C virus (2)
- infection (2)
- sofosbuvir (2)
- therapeutic drug monitoring (2)
- AIDS (1)
- APRI (1)
- ARDS (acute respiratory distress syndrome) (1)
- BRAF mutation (1)
- COVID-19 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- D insufficiency (1)
- D serum-levels (1)
- FIB-4 (1)
- Germany (1)
- HBV (1)
- HCV cure (1)
- HCV genotype 2 (1)
- HCV genotype-2 (1)
- HCV infection (1)
- HIV diagnosis and management (1)
- HIV infections (1)
- HIV-1-infected patients (1)
- HIV-1-infected subjects (1)
- HIV-infected patients (1)
- IL28B polymorphisms (1)
- LINE-1 retrotransposition (1)
- Prednisolon (1)
- Ruxolitinib (1)
- T cells (1)
- Tansania (1)
- Tanzania (1)
- Uganda (1)
- acoustic radiation force impulse imaging (1)
- active antiretroviral therapy (1)
- adults (1)
- afatinib (1)
- all-cause mortality (1)
- antimicrobial resistance (1)
- antiretrovirals (1)
- at-home sampling (1)
- bile (1)
- biomarkers (1)
- chemokines (1)
- chronic Hepatitis C (1)
- cirrhosis (1)
- coagulation (1)
- common genetic determinants (1)
- cytochrome P450 3A4 (CYP3A4) (1)
- cytotoxic T cells (1)
- dabrafenib (1)
- differentiated thyroid tumor (1)
- direct-acting antiviral (1)
- direct-acting antivirals (1)
- disease (1)
- drug adherence (1)
- drug interactions (1)
- drug monitoring (1)
- drug–drug interactions (DDIs) (1)
- elderly persons (1)
- epidemology (1)
- fibrin D-dimer (1)
- fibrotest (1)
- glecaprevir/pibrentasvir (1)
- healthy volunteers (1)
- highly-active antiretroviral therapy (1)
- human hepatic cells (1)
- hydroxy-dabrafenib (1)
- i-131 uptake (1)
- immune activation (1)
- immune cells (1)
- indinavir (1)
- intensive care medicine (1)
- interferon alpha (1)
- interferon-free (1)
- interleukin-6 (1)
- kinase inhibitors (1)
- liquid chromatography tandem mass spectrometry (LC-MS/MS (1)
- liver (1)
- liver diseases (1)
- management (1)
- melanoma (1)
- mutation databases (1)
- non-invasive fibrosis assessment (1)
- osimertinib (1)
- pandemia (1)
- peginterferon alpha-2B (1)
- peginterferon alpha-2b (1)
- pharmacokinetic interaction (1)
- pharmacokinetics (1)
- physiologically based pharmacokinetic (PBPK) modeling (1)
- plasma D-dimer (1)
- point shear wave elastography (1)
- population pharmacokinetics (1)
- posaconazole (1)
- prostate cancer (1)
- randomized controlled-trial (1)
- real world evidence (1)
- reverse-transcriptase inhibitors (1)
- routine clinical-practice (1)
- ruxolitinib (1)
- sequence databases (1)
- severe fibrosis (1)
- steatosis (1)
- sustained virological response (1)
- therapy (1)
- toxicity (1)
- trametinib (1)
- transient elastography (1)
- viral clearance (1)
- viral load (1)
- viral replication (1)
- virus infection (1)
- volumetric absorptive micro-sampling (VAMS) (1)
- weight gain (1)
Institute
- Medizinische Klinik und Poliklinik II (15)
- Institut für Virologie und Immunbiologie (5)
- Medizinische Klinik und Poliklinik I (5)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Mathematik (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Missionsärztliche Klinik (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 241447 (1)
Background
Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients.
Methods
The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores.
Results
At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4–24 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg/m\(^{2}\)) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT.
Conclusion
Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors.